Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon; Richard E. Pratley; Samuel Dagogo‐Jack; James P. Mancuso; Susan Huyck; Urszula Masiukiewicz; B Charbonnel; Robert Frederich; Silvina Gallo; Francesco Cosentino; Weichung Shih; Ira Gantz; Steven G. Terra; David Z.I. Cherney; Darren K. McGuire

doi:10.1056/nejmoa2004967

Abstract

Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).

Keywords

Type 2 diabetesMedicineDiabetes mellitusCardiologyInternal medicineEndocrinology

Affiliated Institutions

Related Publications

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green , M. Angelyn Bethel , Paul W. Armstrong +16 more

Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular ...

2015 New England Journal of Medicine 2519 citations

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

Thierry André , Kai‐Keen Shiu , Tae Won Kim +18 more

Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer...

2020 New England Journal of Medicine 2637 citations

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frías , Melanie J. Davies , Julio Rosenstock +6 more

In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 we...

2021 New England Journal of Medicine 1528 citations

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Marc A. Pfeffer , Brian Claggett , Rafael Díaz +13 more

In patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular ev...

2015 New England Journal of Medicine 2220 citations

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

William B. White , Christopher P. Cannon , Simon Heller +10 more

Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor al...

2013 New England Journal of Medicine 2475 citations

Publication Info

Year: 2020
Type: article
Volume: 383
Issue: 15
Pages: 1425-1435
Citations: 1396
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1396

OpenAlex

Cite This

APA Style

                            
                                
                                    Christopher P. Cannon, 
                                
                                    Richard E. Pratley, 
                                
                                    Samuel Dagogo‐Jack
                                
                                et al.
                            
                            (2020). 
                            Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. 
                            New England Journal of Medicine
                            , 383
                            (15)
                            , 1425-1435.
                            https://doi.org/10.1056/nejmoa2004967
                        

Identifiers

DOI: 10.1056/nejmoa2004967